Key result
Elevated admission HbA1c in non-diabetic STEMI patients is linked to ~621% higher mortality risk.
Why the study?
Elevated HbA1c predicts cardiovascular disease and mortality, but its correlation with short-term mortality in non-diabetic patients with STEMI required evaluation.
Does elevated HbA1c on admission predict 6-month all-cause mortality in non-diabetic patients with STEMI?
Observational (n=266)
No
Does elevated HbA1c on admission predict 6-month all-cause mortality in non-diabetic patients with STEMI?
Odds Ratio: 7.21 (95% CI 2.83–18.36)
p-value: p=<0.001
Elevated HbA1c (>6) on admission is an independent predictor of 6-month all-cause mortality in non-diabetic patients presenting with STEMI.
May aid risk stratification in non-diabetic STEMI; hypothesis-generating pending prospective validation.
Background: Elevated HBA1C level is predictive for cardiovascular disease and mortality in diabetic & also in non-diabetic patients. Aim of our study was to evaluate correlation between HBA1c on admission and short term mortality in non-diabetic patients with ST elevated myocardial infarction. Methods: 266 non-diabetic patients presenting with STEMI (within 48 hours) were included in our study. Data regarding patient characteristics were collected over 7 months. All-cause mortality data collected prospectively up to 6 months. Results: Mean HBA1C was 5.69±0.65 for the study population. HBA1C quartiles (<5, 5.1-5.5, 5.6-6, 6.1-6.4) has shown increased 6 months mortality (3%, 4.8%, 1.7%, 15.1% respectively P=0.004) with increased values. Multivariate regression analysis has shown HBA1C>6 as an independent predictor of 6 month mortality. Conclusion: A significant correlation exists between HBA1C on admission in non-diabetic patients with STEMI and 6 month all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Arnab Ghosh Chaudhury (2020) conducted an observational in ST Elevated Myocardial Infarction (STEMI) in non-diabetic patients (n=266). Elevated HbA1c (>6.0%) vs. Lower HbA1c (≤6.0%) was evaluated on 6-month all-cause mortality (Adj OR 7.21, 95% CI 2.83-18.36, p=<0.001). An admission HbA1c > 6.0% in non-diabetic patients with STEMI was independently associated with a significantly higher risk of 6-month all-cause mortality (Adj OR 7.21).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: